Company: ARVN
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049527
Chunk: 121

Company: ARVINAS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 121
---
 EndedSeptember 30,Nine Months EndedSeptember 30,(dollars in millions)2025202420252024Revenue$41.9 $102.4 $253.1 $204.2 Less:Research and development expenseVepdegestrant (ARV-471) (*)14.2 19.6 53.4 63.8 ARV-1025.0 4.5 15.3 7.5 ARV-806 5.1 0.8 7.7 1.1 ARV-3932.6 1.7 7.7 4.6 Bavdegalutamide (ARV-110)0.3 2.7 2.3 6.8 Luxdegalutamide (ARV-766)— 4.7 — 17.9 Other programs0.3 — 2.8 — Non program-specific external expense12.8 13.7 37.9 43.4 Compensation and related personnel expense(including stock-based compensation)21.6 35.8 88.6 110.4 Other research and development expense2.8 3.4 8.4 9.4 Total research and development expense64.7 86.9 224.1 264.9 General and administrative expense21.0 75.8 72.9 131.3 Other segment expense, net (**)— 2.6 0.4 2.7 Income tax expense0.3 0.6 0.1 1.0 Plus:Interest income, net9.0 14.3 31.0 41.9 Segment net loss$(35.1)$(49.2)$(13.4)$(153.8)(*)    Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.(**)    Includes primarily a write-off of leasehold improvements resulting from the termination of the lease for the Company's laboratory and office space at 101 College Street and realized foreign exchange gains/ losses.During the three months ended September 30, 2025 and 2024, the Company recognized depreciation and amort